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the population was female (56.0%) with a mean Charlson comorbidity score of 0.43. 
Mean age was 21.6 years with 55.7% under the age of 18. The most common OP pro-
cedures were diagnostic (10.3%) while valve and septa operations (15.6%) and heart 
catheterization (11.9%) were the most frequent IP procedures. Mean LOS was 10.4 
days. Congestive heart failure (CHF) (RR 1.31, 95% CI 1.12, 1.51) fluid and electrolyte 
disorders (ED) (RR 1.68 CI1.46, 5.74), and ventricular septal defects (RR 1.33, CI1.09, 
1.62) diagnoses were associated with longer IP stays. 5.0% of patients admitted 
expired in the hospital and 8.5% were readmitted within 30 days. CHF (OR 2.26 CI 
1.10, 5.12), ED (OR 3.51 CI 1.49, 8.62), and cardiac dysrhythmias (OR 2.63 CI 1.22, 8.62), 
were associated with increased mortality. Only CHF (OR 2.64 CI 1.46, 4.68) was associ-
ated with increased readmissions. CONCLUSIONS: While EA patients are typically 
treated in the OP setting hospital utilization is high when IP services are required.
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OBJECTIVES: Thyroid cancer (TC) constitutes ~1% of all diagnosed cancers. DTC is 
the most common type of TC, accounting for about 95% of all cases. Most patients 
with DTC respond well to surgery and/or radioiodine therapy (I-131). However, 
< 5% of patients become refractory to I-131. Disease burden and healthcare costs 
associated with this orphan disease have not been well described. METHODS: This 
retrospective cohort analysis combined data from the Humana and OptumInsight 
Claims databases from Apr2005-Jun2014. Patients age > = 18 years were defined as 
having RAI-R DTC if they received a tyrosine-kinase inhibitor (TKI) and had > = 2 
diagnoses of thyroid cancer (ICD-9 code 193.xx) on or prior to the index date (first 
TKI use). Patients were excluded if no continuous medical/pharmacy coverage in 
the 6-months pre and post-index. Descriptive results included mean all-cause and 
thyroid-related total healthcare cost & utilization (inpatient, outpatient and phar-
macy), and were assessed 6 months post-index then converted to annual estimates. 
Results were reported for both the individual and combined datasets. RESULTS: A 
total of 116 patients ( Humana= 36; Optum= 80 patients) were identified. Mean age 
was 60 years and 45.7% were female. The average time from diagnosis to TKI use 
was 754 days. The most common TKIs were sorafenib (41.4%), sunitinib (26.7%), 
and vandetanib (14.7%), and 31.9% of patients used > = 2 TKIs. The average number 
of outpatient and ER visits were 43.4 and 1.2 for all-cause, and 22.2 and 0.3 for 
thyroid-related, respectively. Rates of hospitalization were 25.0% and 11.2% for all- 
and thyroid-related causes, with a mean stay of 7.8 and 5.1days, respectively. The 
average number of all-cause and thyroid-related prescriptions were 40.9 and 15.7, 
respectively. Total all- and thyroid-related annual healthcare costs were $127,935 
and $97,344, respectively. CONCLUSIONS: RAI-R DTC is a rare disease, with high dis-
ease burden as shown through high rates of healthcare utilization and annual cost.
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OBJECTIVES: We evaluated the economic burden of treating skeletal-related events 
(SREs), including pathologic fractures (PF), spinal cord compression (SCC), radia-
tion to bone (RB) and bone surgery (BS), in prostate cancer (PC) patients with bone 
metastasis (BM). METHODS: PC patients with a BM diagnosis between 01/01/2005 
and 03/01/2012 were identified in the Truven Health Analytics databases. Propensity 
score was used to match BM patients with SREs to those without. A pseudo-SRE date 
was assigned to the control group that was parallel to the SRE date of the matched 
SRE patients. We compared the total and per member per month (PMPM) costs of 
patients between two groups for the 6-month post-SRE/ pseudo-SRE date. RESULTS: 
We identified 4,975 PC men with BM where 910 patients with SREs were 1:1 matched 
to the non-SRE patients. For those men with at least one SRE, 95.8% received RB; 
17.6% had PF; 12% received BS; and 10.4% had SCC. On average, the total 6-month 
costs of treating patients with SREs were $47,724, compared to $24,729 for the 
matched control cohort (p< 0.001). The mean PMPM cost for non-SRE patients was 
$4,122. The largest proportion of differences in costs between two groups incurred 
in the first month after the SRE-index date ($16,564 vs. $4,636, p< 0.001), and were 
mostly attributable to outpatient visits (65.7%, p< 0.001) and inpatient hospitaliza-
tion (29.1%, p< 0.001). CONCLUSIONS: For PC patients with BM, costs of treating 
those with SREs are significantly higher than comparable patients without SREs. 
Most of costs were incurred in the first month after the occurrence of SREs, but 
while costs decreased thereafter, they remained significantly higher for patients 
with SRE in subsequent months.
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OBJECTIVES: Pancreatic cancer is considered one of the toughest cancers to treat, 
with extremely poor prognosis. The objective of this research was to conduct a 
systematic review of epidemiology and the burden of pancreatic cancer. METHODS: 
A systematic literature search for epidemiology and the burden of disease studies 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key find-
ings. Extracted study data included pancreatic cancer incidence, complications, 
cant difference in inpatient costs (p< 0.01) between the 2 groups. CONCLUSIONS: 
The economic burden of patients using new bio-surgical hemostatic materials was 
considerable. While a number of factors affected inpatient costs, patients using ORC 
were associated with lower total inpatient expenditure.
PCN48
systematiC revieW of eCoNomiC evalUatioNs iN allogeNeiC 
HematoPoietiC stem Cell traNsPlaNtatioN
Lachaine J.1, Lachance S.2, Lambert-Obry V.1, Bibeau J.1
1University of Montreal, Montreal, QC, Canada, 2Maisonneuve-Rosemont Hospital, Montreal, QC, 
Canada
OBJECTIVES: The objective of this literature review was to explore the existing evi-
dences regarding cost-effectiveness of allogeneic hematopoietic stem cell transplan-
tation (AHSCT) in hematologic cancers (HCs). METHODS: A systematic literature 
review was performed using the PICO method: Population consisted of patients suf-
fering from HCs; Intervention and Comparators were AHSCT compared to different 
types of AHSCT or standard therapies and Outcomes were incremental cost-utility 
ratios (ICURs) and/or incremental cost-effectiveness ratios (ICERs). The literature 
search was performed with the NHS EED filters using electronic databases from 
1948 until August 2014. RESULTS: The literature review allowed retrieving 5,805 
studies of which 13 fulfilled the eligibility criteria. Three studies included economic 
analysis on acute myeloid leukemia (AML), two on acute lymphoid leukemia (ALL), 
five on acute leukemias, three on chronic myeloid leukemia (CML) and one on 
myelodysplastic syndromes. Nine were cost-effectiveness analyses and four were 
cost-utility analyses. Five studies used a Markov model. The largest proportion of the 
studies compared AHSCT to standard chemotherapy (SC) (n= 5), followed by imatinib 
(n= 2) and various other comparators (n= 6). The time horizon varied from 1 year to 
lifetime. All studies used a health care system perspective. In AML and ALL, ICERs 
ranged from dominant to (2014US)$154,597/LYG compared to SC. In Philadelphia-
positive (Ph+) CML, ICERs for imatinib ranged from dominant to (2014US)$127,013/
QALY compared to AHSCT. CONCLUSIONS: Most of analyzed studies suggest that 
AHSCT is cost-effective in AML and ALL compared to SC, but not in Ph+CML when 
compared to imatinib, despite a wide cost-effectiveness ratios range. This is con-
sistent with current clinical practice in Ph+CML, where tyrosine kinase inhibitors, 
like imatinib, have replaced AHSCT for first-line therapy. Despite the high level of 
heterogeneity among selected studies, this review provides a comprehensive over-
view of the cost-effectiveness of AHSCT in HCs and could serve in the realization 
of future economic evaluations.
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OBJECTIVES: A literature search revealed no prior study on the direct medical 
costs for gynecologic cancer, including uterine, cervical, ovarian and other gyneco-
logic cancers. The study objective was to estimate the direct healthcare costs of 
gynecologic cancers among community-dwelling U.S. residents from an all-payer 
perspective. METHODS: A retrospective cross-sectional analysis was conducted 
using the 2007-2011 Medical Expenditure Panel Survey (MEPS) databases for patients 
with gynecologic cancers. Direct healthcare costs in the U.S. were estimated using 
gynecologic cancer-related expenditures by source of payment and service type. 
Generalized linear models with a gamma distribution and a log link were used 
to estimate adjusted mean expenditures based on patients’ characteristics. Costs 
were adjusted to 2011 U.S. dollars using the Consumer Price Index-Medical (CPI-
M). RESULTS: A total of 282 patients (average annual weighted N= 568,245) were 
identified with gynecologic cancer diagnoses across the study years. The estimated 
annual direct healthcare cost attributable to gynecologic cancers was $3.86 billion. 
The estimated average annual direct healthcare cost per patient was $6,794 (stand-
ard error [SE]= $1,269). Medicare accounted for most of the total expenditures (44%), 
followed by private insurance (38%). Over half (56%) of the total costs were generated 
by inpatient hospitalizations. The annual predicted costs (SE) per patient were $5,887 
($1,059) in patients with one type of gynecologic cancer and $13,129 ($6,573) in 
patients with two different types of gynecologic cancers. The annual predicted cost 
(SE) per patient with ovarian cancer was $15,693 ($7,912), which was higher than that 
for uterine ($9,590±$3,636) and cervical cancers ($7,935±$3,668). CONCLUSIONS: 
Gynecologic cancers place a considerable economic burden on society. The major-
ity of expenditures was driven inpatient hospitalizations and Medicare accounted 
for the largest portion of payments. This study can provide better understanding 
of the economic burden of gynecologic cancers and contribute to future policy on 
gynecologic cancer prevention and control programs.
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OBJECTIVES: Ebstein’s anomaly (EA) is a rare congenital heart disorder affecting the 
tricuspid valve in approximately one out of every 200,000 live births. Treatment for 
EA is focused on reducing symptoms and avoiding disease progression to complica-
tions like heart failure or arrhythmia. The objective of this analysis is to examine 
hospital-based utilization in patients with EA. METHODS: A retrospective cross-
sectional study was conducted on EA discharges in the MedAssets health system 
data for inpatient (IP) and outpatient (OP) visits between January 2009 and December 
2014. Age and gender, hospital characteristics, clinical comorbidities and meas-
ures of utilization including length of stay (LOS) and readmissions were described. 
Multivariable regression was used to identify significant drivers of hospital-based 
utilization. RESULTS: Hospital utilization occurred primarily in the OP setting 
(81.0%) in teaching facilities (88.3%) with 300 or more beds (78.1%). More than half 
